Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215

Benzinga · 3d ago
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.